Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P40938
UPID:
RFC3_HUMAN
Alternative names:
Activator 1 38 kDa subunit; Activator 1 subunit 3; Replication factor C 38 kDa subunit
Alternative UPACC:
P40938; C9JU95; O15252; Q5W0E8
Background:
Replication factor C subunit 3 (RFC3), also known by its alternative names such as Activator 1 38 kDa subunit, plays a crucial role in DNA replication and repair. It functions as a part of the complex necessary for the elongation of primed DNA templates by DNA polymerase delta and epsilon, alongside the accessory proteins proliferating cell nuclear antigen (PCNA) and activator 1.
Therapeutic significance:
Understanding the role of Replication factor C subunit 3 could open doors to potential therapeutic strategies.